| Literature DB >> 28182124 |
Melese Hailu Legese1, Gebru Mulugeta Weldearegay1, Daniel Asrat2.
Abstract
BACKGROUND: Infections by extended-spectrum beta-lactamase- (ESBL) and carbapenem-resistant Enterobacteriaceae (CRE) are an emerging problem in children nowadays. Hence, the aim of this study was to determine the prevalence of ESBL- and carbapenemase-producing Enterobacteriaceae among children suspected of septicemia and urinary tract infections (UTIs).Entities:
Keywords: Addis Ababa; ESBL; Enterobacteriaceae; Ethiopia; Tikur Anbessa Specialized Hospital; carbapenem resistance
Year: 2017 PMID: 28182124 PMCID: PMC5279835 DOI: 10.2147/IDR.S127177
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Frequency of Enterobacteriaceae isolated from blood and urine cultures
| Total | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample | Blood | 5 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 9 |
| Urine | 14 | 5 | 1 | 2 | 0 | 0 | 1 | 0 | 1 | 24 | |
| Total | 19 | 6 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 33 | |
| Patient | Outpatient | 5 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Inpatient | 14 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 24 | |
| Total | 19 | 6 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 33 | |
Antimicrobial resistance levels of Enterobacteriaceae
| Organism isolated | No | Antimicrobial resistance level of | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AML | AMC | SXT | FOX | C | CTX | GM | NOR | TE | FN | IMI | MEM | ||
| 6 | 6 (100) | 6 (100) | 6 (100) | 3 (50) | 4 (66.7) | 4 (66.7) | 4 (66.7) | 4 (66.7) | 5 (83.3) | 0 (0) | 0 (0) | 0 (0) | |
| 2 | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 0 (0) | |
| 1 | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | |
| 1 | 1 (100) | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | |
| 1 | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 0 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | |
| 1 | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| 1 | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 0 (00) | 1 (100) | 0 (0) | 0 (0) | 1 (100) | 1 (100) | 0 (0) | 1 (100) | |
| 19 | 18 (94.7) | 17 (89.5) | 16 (84.2) | 7 (36.8) | 11 (57.9) | 19 (100) | 17 (89.5) | 3 (15.8) | 14 (73.7) | 9 (47.9) | 2 (10.5) | 3 (15.8) | |
| 1 | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Total | 33 | 31 (89.1) | 28 (74.5) | 29 (83.6) | 15 (48.1) | 19 (61.8) | 29 (85.5) | 26 (70.9) | 12 (34.5) | 25 (72.7) | 12 (39.6) | 4 (12.2) | 4 (12.2) |
Abbreviations: AML, amoxicillin; AMC, amoxicillin-clavulanic acid; SXT, sulfamethoxazole-trimethoprim; FOX, cefoxitin; C, chloramphenicol; CTX, cefotaxime; GM, gentamicin; NOR, norfloxacin; TE, tetracycline; FN, nitrofurantoin; IMI, imipenem; MEM, meropenem.